nirmatrelvir

Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial, 2026, Oppegaard et al. Summary Background Long-term symptoms are common after acute COVID-19, particularly fatigue, cognitive problems, and dyspnoea. Cohort studies...

Nirmatrelvir/ritonavir use reduces risk for long COVID in patients with immunodeficiency [Line breaks added] Selected paragraphs Our findings highlight the potential broad benefit of nirmatrelvir/ritonavir in reducing the risk of long COVID among patients with both primary and secondary...

Efficacy Of SARS–CoV-2 Specific Antiviral Therapy for Enteroviral Myalgic Encephalomyelitis/ChronicFatigue Syndrome John K Chia, David Wang Background Etiology remains elusive for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and no treatment exists. Antivirals had no efficacy...

https://www.nature.com/articles/s43856-024-00668-8 Article Open access Published: 06 January 2025 Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series Alison K. Cohen, Toni Wall Jaudon, Eric M. Schurman, Lisa Kava, Julia Moore Vogel, Julia...

Key Points Question Is treatment with nirmatrelvir in the acute phase of SARS-CoV-2 infection associated with a lower risk of post–COVID-19 condition (PCC)? Findings In this cohort study of 281 793 people with SARS-CoV-2 infection who had at least 1 risk factor for progression to severe...